Autopsy report · NCT03597503

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

“Business decision, not related to safety”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 41 participants enrolled.
• Results were posted on the registry 4 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Supernus Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

SPN-810; Placebo

Participants

41

Sites

38

Countries

United States

Trials that died the same way

• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (88% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (85% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (84% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (83% match in meaning)
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
  “Company decision (not a safety issue)” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.